ClinicalTrials.gg
CompletedNCT03995485KW-136_IIIUpdated Jun 25, 2019

KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C

A Phase 3 interventional study of KW-136 capsule and Sofosbuvir in Hepatitis C, Chronic, sponsored by Kawin Technology Share-holding Co., Ltd.. Completed at 19 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-06-25.

Sponsored by Kawin Technology Share-holding Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Jun 2017, registered Jun 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
371
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing sofosbuvir in Hepatitis C, Chronic — none open to participants now, 1 under way, none of them phase 3. Sofosbuvir · Hepatitis C, Chronic.

Enrollment
4th of 50
371 · median 65
Started
2017
with 3 others
Phase 3
11 of 50
none open now
Registered
44th of 50
by date
Lead sponsor
2 of 50
Kawin Technology Share-holding Co., Ltd.

Among the 50 studies testing sofosbuvir in Hepatitis C, Chronic, this one is the 4th largest by enrollment, is one of 4 that started in 2017, is one of 11 in phase 3, and was the 44th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 50 studies testing sofosbuvir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About sofosbuvir

Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing sofosbuvir in Hepatitis C, Chronic as a file.
02

Study summary

This study aimed to confirm efficacy and safety of KW-136, an investigational anti-hepatitis C virus (HCV) drug, combined with sofosbuvir for treatment of naive and experienced adults chronically infected with HCV. Three hundred and sixty (360) non-cirrhotic and cirrhotic subjects were medicated with KW-136 60 mg daily and sofosbuvir 400 mg daily. The treatment course lasted 12 successive weeks; thereafter all the study participants entered into a 12-week treatment-free follow-up period and an additional 12-week extension treatment-free follow-up period.

Read the detailed description

It is estimated that China has a population of over 10 million infected with HCV and also a highly variable HCV genotype geographic distribution. A simple, universal, non-genotype-specific treatment regimen is preferred for anti-HCV treatment in clinical practice and public health. KW-136 and sofosbuvir are potent anti-HCV agents targeting at different HCV proteins, namely, nonstructural protein 5A and 5B, respectively. The combination regimen of KW-136 and sofosbuvir is expected to completely suppress HCV replication in subjects chronically infected with HCV and achieve a sustained virologic response (SVR12), namely, HCV not detected or below a predefined limit in plasma, 12 or 24 weeks after cessation of treatment.

In a previous phase 2 exploratory study, an all-oral, ribavirin-free regiment of KW-136, an investigational HCV NS5A inhibitor, combined with sofosbuvir, demonstrated a \~99% SVR12 in treatment-naive adult subjects chronically infected with major genotypes of HCV found in China, including those with compensatory cirrhosis. This phase 3 study aimed to confirm the efficacy and safety of this combined regimen in a large scale of target patient population, including interferon-experienced subjects. This simple, uniform regimen is expected to be the solution to HCV eradication in China from the perspective of public health.

03

Conditions studied

  • Hepatitis C, Chronic

Keywords

  • Chronic hepatitis C
  • Hepatitis C virus
  • Eradication
  • KW-136
  • Sofosbuvir
  • Nonstructural protein 5A
  • Nonstructural protein 5B
  • Panogentypic regimen
  • Confirmatory study
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged between 18 and 70 years (both inclusive) at the time of informed consenting and of either sex
  • with a (BMI) between 18 and 32 kg/m\^2 (both inclusive)
  • chronically infected with , namely, with positive anti-HCV, HCV RNA or genotyping results at least six (6) months before the screening, or with a liver confirming chronic hepatitis at most twelve (12) months before the screening or within the screening period
  • with anti-HCV positivity and at least once testing result with HCV RNA equaling to or above 10\^4 IU/mL within the screening period
  • with gentoype 1, 2, 3, 4, 5, 6, mixed, indeterminate or other genotype by the centralized laboratory genotyping
  • no more than ten percent (10%) of the enrolled subjects having previously experienced interferon (defined as having received any regulatory agency approved or interferon formulations, including pegylated and regular interferons at least six [6] months before the screening)
  • having not previously experienced any other approved, investigational or unapproved direct antiviral agents against HCV of any source
  • having not previously experienced oral or injective ribavirin within three (3) months before the screening
  • no more than ten percent (10%) of the enrolled patients having advanced fibrosis or compensatory cirrhosis (as documented by liver transient elastography [FibroScan] within the screening period, or liver biopsy within twelve [12] months before the screening or within the screening period, with an evidence priority over FibroScan result and with the most recent biopsy prevailing in case of inconsistency between liver biopsy and FibroScan result), in accordance with the following definitions of liver disease: no advanced fibrosis or cirrhosis, with a liver stiffness modulus (LSM) below 9.6 kPa and/or F0-2 on fibrosis staging; advanced fibrosis, with a LSM equaling to or above 9.6 kPa but below 14.6 kPa and/or F3 on fibrosis staging; and cirrhosis, with a LSM equaling to or above 14.6 kPa and/or F4 on fibrosis staging
  • women of (including women at or under 50 years of age) with negative blood pregnancy test results, and subjects of childbearing potential (including male subjects and their female partners) having no childbearing plan and consenting to voluntarily use effective measures from the screening until six (6) months after the end of treatment
  • lactating women consenting to discontinue nursing from the screening until six (6) months after the end of treatment
  • voluntarily participating in this trial and being able to understand and sign the form

Exclusion criteria

Exclusion Criteria:

  • having previously experienced any or experimental direct antiviral agents against , including protease inhibitor, nonstructural protein (NS) 5A inhibitor or NS5B polymerase inhibitor, before the screening NS5B polymerase or NS5A inhibitors, before the screening
  • having previously experienced interferon-based antiviral regimens within six (6) months before the screening
  • having previously experienced oral or injective ribavirin within three (3) months before the screening
  • having previously experienced any systemic potent immunomodulatory agents, such as or thymosin alfa, excluding nasal, inhalational, topical steroids and/or others, for more than two (2) weeks within six (6) months before the screening, or expected to be exposed to these agents during the study period
  • with virus surface antigen (HBsAg) or anti-human immunodeficient virus () positivity
  • with evidence of decompensatory liver function, including but not limited to total serum (TBIL) above twice (2) of the (ULN), serum albumin (ALB) below 35 g/L or prothrombin activity (PTA) below 60% confirmed on repeated testing, previous or present history of ascites, upper gastrointestinal bleeding and/or hepatic encephalopathy, or with a liver function reserve of class B or C
  • with primary liver cancer confirmed or evidenced by serum alfa-fetoprotein (AFP) above 100 ng/ml or liver imaging study showing suspected nodules
  • with a previous history of liver disease of other causes, including alcoholic liver disease, nonalcoholic steatohepatitis, drug-induced hepatitis, hepatitis, Wilson disease or hemochromatosis
  • with serum (ALT) or asparate aminotransferase (AST) above ten (10) times of the ULN confirmed on repeated testing
  • with white blood cell (WBC) count below 3×10\^9 per liter, below 1.5×10\^9 per liter (or below 1.25×10\^9 per liter for cirrhotics), count below 50×10\^9 per liter, or below 100 g/L confirmed on repeated testing
  • with serum (CLcr) below 50 ml/min using the Cockcroft-Gault formula confirmed on repeated testing
  • with poorly controlled diabetes mellitus ( [HbA1c] above 8.0% confirmed on repeated testing)
  • with psychiatric or neurologic disorders, including previous or family history of psychiatric disorders (especially depression, depressive state, epilepsy or hysteria)
  • with serious cardiovascular disorders, including uncontrolled hypertension (systolic blood pressure at or above 160 mmHg and/or diastolic blood pressure at or above 100 mmHg), heart insufficiency of class III or above, history of myocardial infarction within six (6) months before the screening, history of percutaneous transluminal coronary angioplasty within six (6) months before the screening, unstable angina pectoris, or (Fridericia correction formula QTc = QT×RR\^-1/3) at or above 450 msec for males or 470 msec for females, second- or third-grade atrioventricular block or any other uncontrolled arrhythmias confirmed on repeated electrocardiography on screening
  • with serious hematologic disorders, such as anemia, hemophilia and others
  • with serious kidney diseases, such as chronic kidney disease, kidney insufficiency and others
  • with serious gastrointestinal disorders, such as peptic ulcer, colitis and others
  • with serious respirator disorders, such as active pulmonary tuberculosis, lung infection, , pulmonary interstitial disease and others
  • with active or suspected malignant tumors, or with a previous history of malignant tumors, excluding skin basal cell carcinoma or cervical carcinoma in situ, within five (5) years before the screening
  • with a history of major organ transplantation
  • with a hypersensitive predisposition or a known history of serious allergy, especially to the investigational products and substances
  • with a history of active alcohol or drug abuse within six (6) months before the screening
  • pregnant women or lactating women rejecting or unable to discontinue nursing
  • being unable to discontinue prohibited medications as defined by the protocol
  • having previously participated in clinical studies of any other drugs within three (3) months before the screening
  • being unable or unwilling to provide , or unable to follow the protocol requirements
  • with any other conditions of ineligibility at the discretion of the investigators
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
371 participants (actual)

Study arms

  • Experimental
    KW-136+SOF

    Treatment-naive and experienced subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.

    Drug: KW-136 capsule · Drug: Sofosbuvir

Interventions

  • DrugKW-136 capsule

    KW-136 60 mg was provided in a single capsule of 60 mg.

    Also known as: Coblopasvir

  • Sofosbuvir was provided in a single tablet of 400 mg.

06

What researchers measure

Primary outcomes

  1. Sustained virologic response at 12 weeks after end of treatment (SVR12)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 12 weeks after end of treatment

Secondary outcomes

  1. Sustained virologic response at 4 weeks after end of treatment (SVR4)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 4 weeks after end of treatment

  2. Rapid virologic response at 1 week after initiation of treatment (RVR1)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 1 week after initiation of treatment

  3. Rapid virologic response at 2 weeks after initiation of treatment (RVR2)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 2 weeks after initiation of treatment

  4. Rapid virologic response at 4 weeks after initiation of treatment (RVR4)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 4 weeks after initiation of treatment

  5. Rapid virologic response at 8 weeks after initiation of treatment (RVR8)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 8 weeks after initiation of treatment

  6. Rapid virologic response at 12 weeks after initiation of treatment (RVR12)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 12 weeks after initiation of treatment

Other outcomes

  1. Sustained virologic response at 24 weeks after end of treatment (SVR24)

    Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)

    Time frame: 24 weeks after end of treatment

  2. Virologic breakthrough

    Percentage of subjects with on-treatment re-detected plasma HCV RNA after HCV RNA below the lower limit of quantitation

    Time frame: 2, 4, 8 and 12 weeks after initiation of treatment

  3. Virologic relapse

    Percentage of subjects with off-treatment re-detected plasma HCV RNA after end-of-treatment HCV RNA below the lower limit of quantitation

    Time frame: 4,12 and 24 weeks after end of treatment

07

Study locations

19 sites
  • Chinese PLA 302 Hospital
    Beijing, Beijing 100039, China
  • Capital Medical University Affiliated Beijing Youyi Hospital
    Beijing, Beijing 100050, China
  • Capital Medical University Affiliated Beijing You'an Hospital
    Beijing, Beijing 100069, China
  • Capital Medical University Affiliated Beijing Ditan Hospital
    Beijing, Beijing 100102, China
  • Chinese PLA Third Military Medical University First Affiliated Hospital
    Chongqing, Chongqing 400038, China
  • Chongqing Sanxia Central Hospital
    Wanzhou, Chongqing 404000, China
  • Sun Yat-sen University Affiliated Third University
    Guangzhou, Guangdong 510630, China
  • Guangzhou Municipal Eighth People's Hospital
    Guanzhou, Guangdong 510060, China
  • Liuzhou People's Hospital
    Liuzhou, Guangxi 545006, China
  • He'nan Provincial Hospital of Infectious Disease (Zhengzhou Municipal Sixth People's Hospital)
    Zhengzhou, Henan 450015, China
  • Huazhong University of Science and Technology Affiliated Tongji Hospital
    Wuhan, Hubei 430030, China
  • Nanjing Municipal Second Hospital
    Nanjing, Jiangsu 210003, China
  • Jilin University First Hospital
    Changchun, Jilin 130021, China
  • Yanbian University Affiliated Hosptial
    Yanbian, Jilin 133000, China
  • Shenyang Municipal Sixth People's Hospital
    Shenyang, Liaoning 110006, China
  • Chinese PLA Fourth Military Medical University Tangdu Hospital
    Xi'an, Shaanxi 710038, China
  • Ji'nan Municipal Hospital of Infectious Disease
    Ji'nan, Shandong 250021, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
  • Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital
    Ürümqi, Xinjiang 830000, China
08

References and documents

Individual participant data

Plan to share: No — No IPD plan is included in the study protocol.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Jan 2018, 7 months.

Of 41 industry-sponsored phase 3 interventional studies under Hepatitis C, Chronic, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 50 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2019
First posted
Jun 24, 2019
StartActual
Jun 7, 2017
Primary completionActual
Jan 25, 2018
CompletionActual
Mar 7, 2018
Last update
Jun 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03995485
Lead sponsor
Kawin Technology Share-holding Co., Ltd.
Collaborators
KawinGreen Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Jun 24, 2019
Start date
Jun 7, 2017
Primary completion
Jan 25, 2018
Completion
Mar 7, 2018
Last update
Jun 25, 2019

Study contacts

Junqi Niu, M.D.
principal investigator · First Hospital of Jilin Univerisity
Lai Wei, M.D.
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sofosbuvir

Start the discussion